DEA Telemedicine Rule Changes for NPs in 2026: What Actually Changed and What Did Not

If you are a nurse practitioner who prescribes controlled substances over telehealth, the most important thing to know in 2026 is this: the pandemic-era flexibilities that let you prescribe Schedule II through V controlled substances by video without a prior in-person visit are still in place, now extended through December 31, 2026. Nothing about your day-to-day prescribing changed on January 1. What changed sits underneath that headline, and it matters for any NP building a multi-state telehealth practice.

Where things standThe short version

On December 31, 2025, the Drug Enforcement Administration, working jointly with the Department of Health and Human Services, issued a Fourth Temporary Extension of the COVID-era telemedicine flexibilities. It runs from January 1, 2026 through December 31, 2026. Under it, a DEA-registered practitioner may prescribe Schedule II through V controlled medications through an audio-video telemedicine encounter without ever having conducted an in-person evaluation of the patient, provided the prescription otherwise complies with DEA regulations and applicable federal and state law. Audio-only telemedicine remains permitted in the limited case of FDA-approved medications used to treat opioid use disorder.

The extension adds no new requirements. It continues the status quo that has existed since 2020. The DEA's stated reason for extending again, rather than letting the rules lapse, is to avoid what regulators call a telemedicine cliff and to buy time to finalize a permanent framework.

BackgroundWhy these flexibilities exist

Under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, a practitioner generally may only prescribe a controlled substance over the internet after at least one in-person medical evaluation of the patient, with narrow exceptions. When the COVID-19 public health emergency was declared in 2020, the DEA waived that in-person requirement. The emergency ended in May 2023, but the waiver did not. The DEA has kept it alive through a series of temporary extensions, the most recent being this fourth one.

Two narrower final rules also became permanent on December 31, 2025:

• Buprenorphine for opioid use disorder via telemedicine — now permanent. NPs treating OUD with buprenorphine can continue using telehealth without an in-person visit, including audio-only encounters where appropriate.
• VA continuity of care — permanent rule covering Veterans Affairs patients receiving telemedicine prescribing for controlled substances.

For most NPs in private telehealth or platform-based practice, the Fourth Temporary Extension is the authority you are operating under, and it carries fewer requirements than either final rule.

On the horizonThe big change still coming: Special Registration

The reason regulators keep using the word "temporary" is that a permanent replacement has been proposed but not finalized. In January 2025, the DEA published a proposed rule titled Special Registrations for Telemedicine and Limited State Telemedicine Registrations. As of mid-2026 it has not been finalized, and the current administration has not signaled whether it will move it forward, revise it, or withdraw it. It is not law, and you do not need to do anything about it today. But it is the most likely shape of the future, so it is worth understanding.

The proposal would create new registration categories layered on top of your existing DEA registration, including:

• A separate State Telemedicine Registration for each state where a patient receiving a telemedicine prescription is located
• Electronic prescribing for controlled substances (federal mandate, on top of state EPCS rules that already exist in NY, CA, and others)
• Patient identity verification with a government-issued photo ID
• Expanded prescription drug monitoring program (PDMP) checks that would eventually reach all fifty states
• Tighter limits on Schedule II telemedicine prescribing specifically

Industry and hospital groups have pushed back hard, particularly on the nationwide PDMP check, and whether the final rule keeps those provisions or softens them is genuinely unresolved. The practical takeaway is not to build your workflow around the proposal yet, but to watch it, because if it lands it will reshape multi-state telehealth prescribing.

The part most coverage missesFederal rule is only half the picture

Here is the piece that gets lost in most coverage. The DEA flexibility is a federal ceiling on what is permitted. It does not override the floor set by each individual state, and for nurse practitioners that floor varies enormously.

The federal rule says a DEA-registered practitioner may prescribe Schedule II through V by video. It does not say you, specifically, have the authority to prescribe those schedules in the state where your patient sits. That comes from state law. An NP's prescriptive authority, the specific schedules an NP may write for, whether a separate state controlled substance registration is required on top of the federal DEA number, whether a collaborative or supervisory agreement must be in place, and whether and when you must query the state PDMP — all of that is set state by state. A federal flexibility cannot grant you authority your practice state withholds.

For a single-state NP this is manageable. For a telehealth NP licensed in eight or twelve states, it becomes a real matrix. Every state you treat patients in brings its own scheduling, its own registration steps, and its own PDMP query triggers. The DEA can tell you the in-person requirement is waived nationwide. Only the individual state can tell you what you are allowed to prescribe there and what you must do first.

Quick referenceState-layered rules in the highest-volume APRN states

A non-exhaustive snapshot of the state-level rules that apply in addition to (not instead of) the federal DEA framework:

State	State-layered telehealth CS rule
California	NPs must hold a CA Furnishing Number ($400 application) to prescribe any medication, including via telehealth. CURES 2.0 (CA's PDMP) query required within 24 hours before prescribing Schedule II–IV, then at least every 6 months during ongoing treatment, regardless of telehealth. E-prescribing required for nearly all prescriptions including controlled substances (AB 2789, effective Jan 2022).
Texas	APRNs need an active Prescriptive Authority Agreement (PAA) with a TX-licensed physician. Schedule II prescriptions via telehealth are restricted to hospital facility-based practice or hospice care only — even with the federal flexibility in place. Schedule III–V via telehealth allowed under PAA + DEA. PMP-Aware query required for opioids, benzodiazepines, barbiturates, and carisoprodol regardless of where you're physically located.
Florida	Schedule II controlled substances may not be prescribed via telehealth except for: (1) psychiatric disorders, (2) inpatient hospital treatment, (3) hospice services, or (4) nursing home residents (§456.47(4)(c), Fla. Stat.). Out-of-state telehealth providers serving FL patients must register at flhealthsource.gov/telehealth/ under §456.47 — distinct from the FL APRN license. E-FORCSE query required before prescribing CS Schedule II–V to patients age 16+.
New York	I-STOP mandates electronic prescribing for ALL prescriptions in NY (controlled and non-controlled), with limited DOH-granted hardship waivers. Prescription Monitoring Program query required before prescribing Schedule II–IV. DEA-registered NPs must complete 3 hrs pain management / palliative care / addiction every 3 years per Public Health Law §3309-a.
Pennsylvania	CRNPs need a Prescriptive Authority Collaborative Agreement filed with the Bureau of Professional and Occupational Affairs. ABC-MAP PDMP query required before initially prescribing opioids or benzodiazepines and at least quarterly for ongoing treatment. Act 124 opioid CE for prescribers: 2 hrs every biennial renewal cycle.

Even in the best-case federal scenario (a Fifth Temporary Extension continuing telehealth flexibility), these state-level rules persist. They're independent of the DEA's framework and have to be tracked separately.

Action itemsWhat to do right now

Through the end of 2026 you can continue prescribing controlled substances by audio-video telehealth without a prior in-person visit, as long as you hold a valid DEA registration and your prescription complies with the law in both the state where you practice and the state where your patient is located. Specifically:

1. Keep your DEA registration current where required

If you maintain DEA registrations in multiple states (one per practice address), make sure each is current and the address on file is accurate. The Fourth Temporary Extension covers cross-state telehealth, but only if your federal credentials are in order.

2. Verify your state-by-state prescribing footprint

For every state you treat patients in, confirm three things: (a) which schedules your NP license actually authorizes you to prescribe, (b) whether that state requires a separate state controlled substance registration on top of federal DEA, and (c) when it requires a PDMP check (initial visit, every refill, quarterly, etc.).

3. Confirm state PDMP enrollment is active everywhere you prescribe

State PDMP enrollment is independent of federal DEA and several states require active enrollment before any controlled substance prescription — CA's CURES, FL's E-FORCSE, NY's I-STOP, TX's PMP-Aware, PA's ABC-MAP. Renewals lapse; check each one this quarter.

4. Document your PDMP review workflow

Many states' rules require not just that you check the PDMP, but that you document the check in the patient's chart. If you ever face a Board investigation or audit, the question won't be "did you check?" — it will be "where in the chart is the timestamped record of the check?"

5. Watch for movement on the Special Registration rule

Subscribe to email alerts from the DEA Diversion Control Division. If the Special Registration proposal is finalized, you'll want lead time to prepare — particularly if it requires per-state telemedicine registration on top of what you already maintain.

Wrap-upThe bottom line

For 2026, the headline is stability. The flexibilities you have relied on since 2020 are extended through December 31, the buprenorphine and VA rules are now permanent, and the larger Special Registration framework remains a proposal. The real complexity for nurse practitioners is not the federal rule, which is simple to state. It is the interaction between that rule and fifty different sets of state controlled substance laws.

This article is general information for nurse practitioners and is not legal or compliance advice. Always confirm current requirements with the DEA and with the Board of Nursing or Board of Pharmacy in every state where you practice. See our Terms of Use and Privacy Policy.